Last reviewed · How we verify
Phospholine Iodide (ECHOTHIOPHATE)
Phospholine Iodide (ECHOTHIOPHATE) is a small molecule cholinesterase inhibitor developed by WYETH PHARMS INC and currently owned by Fera Pharms Llc. It targets acetylcholinesterase to treat various conditions, including esotropia, glaucoma, open-angle glaucoma, and Stargardt's disease. FDA approved in 1960, it is an off-patent medication with no active Orange Book patents. As a result, there are no generic manufacturers available. This medication is used to increase acetylcholine levels in the body, which can help relax muscles and improve vision.
At a glance
| Generic name | ECHOTHIOPHATE |
|---|---|
| Sponsor | Fera Pharms Llc |
| Drug class | Cholinesterase Inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1960 |
Approved indications
- Esotropia
- Glaucoma
- Open-angle glaucoma
- Stargardt's disease
Common side effects
- Stinging
- Burning
- Lacrimation
- Lid muscle twitching
- Conjunctival redness
- Ciliary redness
- Browache
- Induced myopia
- Visual blurring
Serious adverse events
- Retinal detachment
- Iris cysts
- Activation of latent iritis
- Activation of latent uveitis
- Lens opacities
- Conjunctival thickening
- Obstruction of nasolacrimal canals
- Paradoxical increase in IOP
- Cardiac irregularities
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |